MERRIMACK PHARMACEUTICALS IN's ticker is MACKXXXX and the CUSIP is 590328100. A total of 118 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q1 2017. The put-call ratio across all filers is 1.86 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $104,000 | -59.8% | 83,973 | -0.1% | 0.00% | – |
| Q1 2017 | $259,000 | -25.4% | 84,040 | -1.2% | 0.00% | – |
| Q4 2016 | $347,000 | +2.7% | 85,040 | +59.9% | 0.00% | – |
| Q3 2016 | $338,000 | +5.6% | 53,193 | -10.2% | 0.00% | – |
| Q2 2016 | $320,000 | -45.3% | 59,211 | -15.2% | 0.00% | – |
| Q1 2016 | $585,000 | +16.5% | 69,842 | +9.9% | 0.00% | – |
| Q4 2015 | $502,000 | +43.8% | 63,576 | +54.6% | 0.00% | – |
| Q3 2015 | $349,000 | -32.6% | 41,124 | -1.9% | 0.00% | – |
| Q2 2015 | $518,000 | +175.5% | 41,904 | +161.8% | 0.00% | – |
| Q1 2015 | $188,000 | +97.9% | 16,008 | +90.4% | 0.00% | – |
| Q4 2014 | $95,000 | -39.5% | 8,408 | -52.8% | 0.00% | – |
| Q3 2014 | $157,000 | +12.9% | 17,818 | -6.3% | 0.00% | – |
| Q2 2014 | $139,000 | 0.0% | 19,011 | -31.0% | 0.00% | – |
| Q1 2014 | $139,000 | – | 27,566 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 5,000,000 | $20,400,000 | 4.19% |
| Consonance Capital Management LP | 9,067,998 | $36,997,000 | 4.06% |
| Lagoda Investment Management, L.P. | 1,522,529 | $6,212,000 | 2.13% |
| INDUS CAPITAL PARTNERS, LLC | 1,050,000 | $4,284,000 | 0.56% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 9,072,877 | $37,017,000 | 0.32% |
| GARRISON BRADFORD & ASSOCIATES INC | 77,700 | $317,000 | 0.29% |
| Cannell & Co. | 1,572,978 | $6,418,000 | 0.23% |
| Virtus ETF Advisers LLC | 179,625 | $733,000 | 0.22% |
| LeJeune Puetz Investment Counsel LLC | 3,976 | $161,000 | 0.12% |
| STONERIDGE INVESTMENT PARTNERS LLC | 221,838 | $905,000 | 0.12% |